Advances in the Bioactivities of Phytochemical Saponins in the Prevention and Treatment of Atherosclerosis
Abstract
:1. Introduction
2. Ginsenosides
3. Soyasaponins
4. Astra-galosides
5. Glycyrrhizins
6. Gypenosides
7. Dioscins
8. Saiko-saponins
9. Other Saponins
10. Outlook
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Fuster, V.; Badimon, L.; Badimon, J.J.; Chesebro, J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes. N. Engl. J. Med. 1992, 326, 310–318. [Google Scholar] [PubMed]
- Zibaeenejad, F.; Mohammadi, S.S.; Sayadi, M.; Safari, F.; Zibaeenezhad, M.J. Ten-year atherosclerosis cardiovascular disease (ASCVD) risk score and its components among an Iranian population: A cohort-based cross-sectional study. BMC Cardiovasc. Disord. 2022, 22, 162. [Google Scholar] [CrossRef] [PubMed]
- Chandra, N.C. Atherosclerosis and carcinoma: Two facets of dysfunctional cholesterol homeostasis. J. Biochem. Mol. Toxicol. 2020, 34, e22595. [Google Scholar] [CrossRef] [PubMed]
- Chandrasekar, B.; Alanbaei, M. Intracoronary imaging identifies plaque rupture underlying left main thrombosis in acute myocardial infarction without angiographically evident atherosclerosis. Eur. Heart J. 2020, 41, 4448. [Google Scholar] [CrossRef] [PubMed]
- Bundy, J.D.; Heckbert, S.R.; Chen, L.Y.; Lloyd-Jones, D.M.; Greenland, P. Evaluation of risk prediction models of atrial fibrillation (from the multi-ethnic study of atherosclerosis [MESA]). Am. J. Cardiol. 2020, 125, 55–62. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bittner, D.O.; Goeller, M.; Zopf, Y.; Achenbach, S.; Marwan, M. Early-onset coronary atherosclerosis in patients with low levels of omega-3 fatty acids. Eur. J. Clin. Nutr. 2020, 74, 651–656. [Google Scholar] [CrossRef]
- Blekkenhorst, L.C.; Lewis, J.R.; Bondonno, C.P.; Sim, M.; Devine, A.; Zhu, K.; Lim, W.H.; Woodman, R.J.; Beilin, L.J.; Thompson, P.L.; et al. Vegetable diversity in relation with subclinical atherosclerosis and 15-year atherosclerotic vascular disease deaths in older adult women. Eur. J. Nutr. 2020, 59, 217–230. [Google Scholar] [CrossRef]
- Soltani, S.; Boozari, M.; Cicero, A.F.G.; Jamialahmadi, T.; Sahebkar, A. Effects of phytochemicals on macrophage cholesterol efflux capacity: Impact on atherosclerosis. Phytother. Res. 2021, 35, 2854–2878. [Google Scholar] [CrossRef]
- Rampin, A.; Carabba, M.; Mutoli, M.; Eman, C.L.; Testa, G.; Madeddu, P.; Spinetti, G. Recent advances in KEAP1/Nrf2-targeting strategies by phytochemical antioxidants, nanoparticles, and biocompatible scaffolds for the treatment of diabetic cardiovascular complications. Antioxid. Redox Signal. 2022, 36, 707–728. [Google Scholar] [CrossRef]
- Bashir, N.; Manoharan, V.; Miltonprabu, S. Grape seed proanthocyanidins protects against cadmium induced oxidative pancreatitis in rats by attenuating oxidative stress, inflammation and apoptosis via Nrf-2/HO-1 signaling. J. Nutr. Biochem. 2016, 32, 128–141. [Google Scholar] [CrossRef]
- Zhang, Y.; Chen, F.; Chen, J.; Huang, S.; Chen, J.; Huang, J.; Li, N.; Sun, S.; Chu, X.; Zha, L. Soyasaponin Bb inhibits the recruitment of toll-like receptor 4 (TLR4) into lipid rafts and its signaling pathway by suppressing the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-dependent generation of reactive oxygen species. Mol. Nutr. Food Res. 2016, 60, 1532–1543. [Google Scholar] [CrossRef] [PubMed]
- Liu, C.; Chen, C.; Yang, F.; Li, X.; Cheng, L.; Song, Y. Phytic acid improves intestinal mucosal barrier damage and reduces serum levels of proinflammatory cytokines in a 1,2-dimethylhydrazine-induced rat colorectal cancer model. Br. J. Nutr. 2018, 120, 121–130. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- El Badawy, S.A.; Ogaly, H.A.; Abd-Elsalam, R.M.; Azouz, A.A. Benzyl isothiocyanates modulate inflammation, oxidative stress, and apoptosis via Nrf2/HO-1 and NF-kappaB signaling pathways on indomethacin-induced gastric injury in rats. Food Funct. 2021, 12, 6001–6013. [Google Scholar] [CrossRef]
- Ugwor, E.I.; Ugbaja, R.N.; James, A.S.; Dosumu, O.A.; Thomas, F.C.; Ezenandu, E.O.; Graham, R.E. Inhibition of fat accumulation, lipid dysmetabolism, cardiac inflammation, and improved nitric oxide signalling mediate the protective effects of lycopene against cardio-metabolic disorder in obese female rats. Nutr. Res. 2022, 104, 140–153. [Google Scholar] [CrossRef]
- Guclu-Ustundag, O.; Mazza, G. Saponins: Properties, applications and processing. Crit. Rev. Food Sci. Nutr. 2007, 47, 231–258. [Google Scholar] [CrossRef] [PubMed]
- Del Hierro, J.N.; Herrera, T.; Fornari, T.; Reglero, G. The gastrointestinal behavior of saponins and its significance for their bioavailability and bioactivities. J. Funct. Foods 2018, 40, 484–497. [Google Scholar] [CrossRef]
- He, Y.; Hu, Z.; Li, A.; Zhu, Z.; Yang, N.; Ying, Z.; He, J.; Wang, C.; Yin, S.; Cheng, S. Recent advances in biotransformation of saponins. Molecules 2019, 24, 2365. [Google Scholar] [CrossRef] [Green Version]
- Van Dyck, S.; Gerbaux, P.; Flammang, P. Qualitative and quantitative saponin contents in five sea cucumbers from the Indian ocean. Mar. Drugs 2010, 8, 173–189. [Google Scholar] [CrossRef]
- Sharma, A.; Lee, H.J. Ginsenoside compound K: Insights into recent studies on pharmacokinetics and health-promoting activities. Biomolecules 2020, 10, 1028. [Google Scholar] [CrossRef]
- Christensen, L.P.; John, L. Ginsenosides: Chemistry, biosynthesis, analysis, and potential health effects. Adv. Food Nutr. Res. 2009, 55, 1–99. [Google Scholar]
- Wang, Y.; Wu, J.; Zhu, J.; Ding, C.; Xu, W.; Hao, H.; Zhang, J.; Wang, G.; Cao, L. Ginsenosides regulation of lysophosphatidylcholine profiles underlies the mechanism of Shengmai Yin in attenuating atherosclerosis. J. Ethnopharmacol. 2021, 277, 114223. [Google Scholar] [CrossRef] [PubMed]
- Baek, K.S.; Hong, Y.D.; Kim, Y.; Sung, N.Y.; Yang, S.; Lee, K.M.; Park, J.Y.; Park, J.S.; Rho, H.S.; Shin, S.S.; et al. Anti-inflammatory activity of AP-SF, a ginsenoside-enriched fraction, from Korean ginseng. J. Ginseng Res. 2015, 39, 155–161. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, J.; Huang, M.; Teoh, H.; Man, R.Y. Panax quinquefolium saponins protects low density lipoproteins from oxidation. Life Sci. 1999, 64, 53–62. [Google Scholar] [CrossRef]
- Shi, G.; Liu, D.; Zhou, B.; Liu, Y.; Hao, B.; Yu, S.; Wu, L.; Wang, M.; Song, Z.; Wu, C.; et al. Ginsenoside Rb1 alleviates oxidative low-density lipoprotein-induced vascular endothelium senescence via the SIRT1/beclin-1/autophagy axis. J. Cardiovasc. Pharmacol. 2020, 75, 155–167. [Google Scholar] [CrossRef] [PubMed]
- Zhou, P.; Lu, S.; Luo, Y.; Wang, S.; Yang, K.; Zhai, Y.; Sun, G.; Sun, X. Attenuation of TNF-alpha-induced inflammatory injury in endothelial cells by ginsenoside Rb1 via inhibiting NF-kappaB, JNK and p38 signaling pathways. Front. Pharmacol. 2017, 8, 464. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zheng, Z.; Wang, M.; Cheng, C.; Liu, D.; Wu, L.; Zhu, J.; Qian, X. Ginsenoside Rb1 reduces H2O2-induced HUVEC dysfunction by stimulating the sirtuin1/AMPactivated protein kinase pathway. Mol. Med. Rep. 2020, 22, 247–256. [Google Scholar] [CrossRef] [PubMed]
- Zhou, W.; Chai, H.; Lin, P.H.; Lumsden, A.B.; Yao, Q.; Chen, C. Ginsenoside Rb1 blocks homocysteine-induced endothelial dysfunction in porcine coronary arteries. J. Vasc. Surg. 2005, 41, 861–868. [Google Scholar] [CrossRef] [Green Version]
- Lu, H.; Zhou, X.; Kwok, H.H.; Dong, M.; Liu, Z.; Poon, P.Y.; Luan, X.; Ngok-Shun Wong, R. Ginsenoside-Rb1-mediated anti-angiogenesis via regulating PEDF and miR-33a through the activation of PPAR-gamma pathway. Front. Pharmacol. 2017, 8, 783. [Google Scholar] [CrossRef] [Green Version]
- Qiao, L.; Zhang, X.; Liu, M.; Liu, X.; Dong, M.; Cheng, J.; Zhang, X.; Zhai, C.; Song, Y.; Lu, H.; et al. Ginsenoside Rb1 enhances atherosclerotic plaque stability by improving autophagy and lipid metabolism in macrophage foam cells. Front. Pharmacol. 2017, 7, 727. [Google Scholar] [CrossRef] [Green Version]
- Zhang, X.; Liu, M.H.; Qiao, L.; Zhang, X.Y.; Liu, X.L.; Dong, M.; Dai, H.Y.; Ni, M.; Luan, X.R.; Guan, J.; et al. Ginsenoside Rb1 enhances atherosclerotic plaque stability by skewing macrophages to the M2 phenotype. J. Cell. Mol. Med. 2018, 22, 409–416. [Google Scholar] [CrossRef] [Green Version]
- Yang, X.; Wang, L.; Zhang, Z.; Hu, J.; Liu, X.; Wen, H.; Liu, M.; Zhang, X.; Dai, H.; Ni, M.; et al. Rb1 enhances plaque stability and inhibits adventitial vasa vasorum via the modulation of miR-33 and PEDF. Front. Cardiovas. Med. 2021, 8, 654670. [Google Scholar] [CrossRef] [PubMed]
- Nanao-Hamai, M.; Son, B.K.; Komuro, A.; Asari, Y.; Hashizume, T.; Takayama, K.I.; Ogawa, S.; Akishita, M. Ginsenoside Rb1 inhibits vascular calcification as a selective androgen receptor modulator. Eur. J. Pharmacol 2019, 859, 172546. [Google Scholar] [CrossRef] [PubMed]
- Yin, M.; Lin, J.; Yang, M.; Li, C.; Wu, P.; Zou, J.; Jiang, Y.; Shao, J. Platelet membrane-cloaked selenium/ginsenoside Rb1 nanosystem as biomimetic reactor for atherosclerosis therapy. Colloids Surf. B Biointerfaces 2022, 214, 112464. [Google Scholar] [CrossRef]
- Sun, J.L.; Abd El-Aty, A.M.; Jeong, J.H.; Jung, T.W. Ginsenoside Rb2 ameliorates LPS-induced inflammation and ER Stress in HUVECs and THP-1 cells via the AMPK-mediated pathway. Am. J. Chin. Med. 2020, 48, 967–985. [Google Scholar] [CrossRef] [PubMed]
- Chen, Y.; Wang, S.; Yang, S.; Li, R.; Yang, Y.; Chen, Y.; Zhang, W. Inhibitory role of ginsenoside Rb2 in endothelial senescence and inflammation mediated by microRNA216a. Mol. Med. Rep. 2021, 23, 415. [Google Scholar] [CrossRef] [PubMed]
- Geng, J.; Fu, W.; Yu, X.; Lu, Z.; Liu, Y.; Sun, M.; Yu, P.; Li, X.; Fu, L.; Xu, H.; et al. Ginsenoside Rg3 alleviates ox-LDL induced endothelial dysfunction and prevents atherosclerosis in ApoE(−/−) mice by regulating PPARgamma/FAK signaling pathway. Front. Pharmacol. 2020, 11, 500. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Guo, M.; Xiao, J.; Sheng, X.; Zhang, X.; Tie, Y.; Wang, L.; Zhao, L.; Ji, X. Ginsenoside Rg3 mitigated AS progression in diabetic ApoE−/− mice by skewing macrophages to the M2 phenotype. Front. Pharmacol. 2018, 9, 464. [Google Scholar] [CrossRef] [Green Version]
- Guo, M.; Guo, G.; Xiao, J.; Sheng, X.; Zhang, X.; Tie, Y.; Cheng, Y.K.; Ji, X. Ginsenoside Rg3 stereoisomers differentially inhibit vascular smooth muscle cell proliferation and migration in diabetic atherosclerosis. J. Cell. Mol. Med. 2018, 22, 3202–3214. [Google Scholar] [CrossRef] [Green Version]
- Yang, R.; Yin, D.; Yang, D.; Liu, X.; Zhou, Q.; Pan, Y.; Li, J.; Li, S. Xinnaokang improves cecal microbiota and lipid metabolism to target atherosclerosis. Lett. Appl. Microbiol. 2021, 73, 779–792. [Google Scholar] [CrossRef]
- Zhang, L.; Li, Y.; Ma, X.; Liu, J.; Wang, X.; Zhang, L.; Li, C.; Li, Y.; Yang, W. Ginsenoside Rg1-notoginsenoside R1-protocatechuic aldehyde reduces atherosclerosis and attenuates low-shear stress-induced vascular endothelial cell dysfunction. Front. Pharmacol. 2020, 11, 588259. [Google Scholar] [CrossRef]
- Yang, P.; Ling, L.; Sun, W.; Yang, J.; Zhang, L.; Chang, G.; Guo, J.; Sun, J.; Sun, L.; Lu, D. Ginsenoside Rg1 inhibits apoptosis by increasing autophagy via the AMPK/mTOR signaling in serum deprivation macrophages. Acta Biochim. Biophys. Sin. 2018, 50, 144–155. [Google Scholar] [CrossRef] [PubMed]
- Cho, Y.S.; Kim, C.H.; Ha, T.S.; Lee, S.J.; Ahn, H.Y. Ginsenoside rg2 inhibits lipopolysaccharide-induced adhesion molecule expression in human umbilical vein endothelial cell. Korean J. Physiol. Pharmacol. 2013, 17, 133–137. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Xu, H.; Jiang, Y.; Yu, K.; Zhang, X.; Shi, Y. Effect of Ginsenoside Rh1 on proliferation, apoptosis, and oxidative stress in vascular endothelial cells by regulation of the nuclear erythroid 2-related factor-2/heme oxygenase-1 signaling pathway. J. Cardiovasc. Pharmacol. 2022, 79, 335–341. [Google Scholar] [CrossRef]
- Qin, M.; Luo, Y.; Lu, S.; Sun, J.; Yang, K.; Sun, G.; Sun, X. Ginsenoside F1 ameliorates endothelial cell inflammatory injury and prevents atherosclerosis in mice through A20-mediated suppression of NF-κB signaling. Front. Pharmacol. 2017, 8, 953. [Google Scholar] [CrossRef] [Green Version]
- Shen, J.W.; Li, C.; Yang, M.Y.; Lin, J.F.; Yin, M.D.; Zou, J.J.; Wu, P.Y.; Chen, L.; Song, L.X.; Shao, J.W. Biomimetic nanoparticles: U937 cell membranes based core-shell nanosystems for targeted atherosclerosis therapy. Int. J. Pharm. 2022, 611, 121297. [Google Scholar] [CrossRef] [PubMed]
- Lee, E.S.; Choi, J.S.; Kim, M.S.; You, H.J.; Ji, G.E.; Kang, Y.H. Ginsenoside metabolite compound K differentially antagonizing tumor necrosis factor-alpha-induced monocyte-endothelial trafficking. Chem. Biol. Interact. 2011, 194, 13–22. [Google Scholar] [CrossRef]
- Park, E.S.; Lee, K.P.; Jung, S.H.; Lee, D.Y.; Won, K.J.; Yun, Y.P.; Kim, B. Compound K, an intestinal metabolite of ginsenosides, inhibits PDGF-BB-induced VSMC proliferation and migration through G1 arrest and attenuates neointimal hyperplasia after arterial injury. Atherosclerosis 2013, 228, 53–60. [Google Scholar] [CrossRef]
- Zhou, L.; Zheng, Y. Compound K attenuates the development of atherosclerosis in ApoE−/− mice via LXRα activation. Int. J. Mol. Sci. 2016, 17, 1054. [Google Scholar] [CrossRef]
- Huang, Y.; Liu, H.; Zhang, Y.; Li, J.; Wang, C.; Zhou, L.; Jia, Y.; Li, X. Synthesis and biological evaluation of Ginsenoside compound K derivatives as a novel class of LXRalpha activator. Molecules 2017, 22, 1232. [Google Scholar] [CrossRef]
- Lu, S.; Luo, Y.; Zhou, P.; Yang, K.; Sun, G.; Sun, X. Ginsenoside compound K protects human umbilical vein endothelial cells against oxidized low-density lipoprotein-induced injury via inhibition of nuclear factor-kappaB, p38, and JNK MAPK pathways. J. Ginseng Res. 2019, 43, 95–104. [Google Scholar] [CrossRef]
- Lu, S.; Luo, Y.; Sun, G.; Sun, X. Ginsenoside compound K attenuates ox-LDL-mediated macrophage inflammation and foam cell formation via autophagy induction and modulating NF-kappaB, p38, and JNK MAPK signaling. Front. Pharmacol. 2020, 11, 567238. [Google Scholar] [CrossRef] [PubMed]
- Guang, C.; Chen, J.; Sang, S.; Cheng, S. Biological functionality of soyasaponins and soyasapogenols. J. Agric. Food Chem. 2014, 62, 8247–8255. [Google Scholar] [CrossRef] [PubMed]
- Xiong, F.; Zheng, Z.; Xiao, L.; Su, C.; Chen, J.; Gu, X.; Tang, J.; Zhao, Y.; Luo, H.; Zha, L. Soyasaponin A2 alleviates steatohepatitis possibly through regulating bile acids and gut microbiota in the methionine and choline-deficient (MCD) diet-induced nonalcoholic steatohepatitis (NASH) mice. Mol. Nutr. Food Res. 2021, 65, e2100067. [Google Scholar] [CrossRef] [PubMed]
- Xie, Q.; Gu, X.; Chen, J.; Liu, M.; Xiong, F.; Wu, X.; Zhang, Y.; Chen, F.; Chen, H.; Li, M.; et al. Soyasaponins reduce inflammation and improve serum lipid profiles and glucose homeostasis in high fat diet-induced obese mice. Mol. Nutr. Food Res. 2018, 62, e1800205. [Google Scholar] [CrossRef] [PubMed]
- Yin, X.Z.; Quan, J.S.; Takemichi, K. Anti-atherosclerotic effect of soybean isofalvones and soyasaponins in diabetic rats. Chin. J. Prev Med. 2004, 38, 26–28. [Google Scholar]
- Xie, Q.; Xiong, F.; Wu, X.; Chen, J.; Gu, X.; Su, C.; Xiao, L.; Zheng, Z.; Wei, Y.; Ullah, H.; et al. Soyasaponins A1 and A2 exert anti-atherosclerotic functionalities by decreasing hypercholesterolemia and inflammation in high fat diet (HFD)-fed ApoE(−/−) mice. Food Funct. 2020, 11, 253–269. [Google Scholar] [CrossRef]
- Kang, J.; Badger, T.M.; Ronis, M.J.J.; Wu, X. Non-isoflavone phytochemicals in soy and their health effects. J. Agric. Food Chem. 2010, 58, 8119–8133. [Google Scholar] [CrossRef]
- Potter, J.D.; Topping, D.L.; Oakenfull, D. Soy, saponins, and plasma cholesterol. Lancet 1979, 1, 223. [Google Scholar] [CrossRef]
- Harris, W.; Dujovne, C.; Windsor, S.; Gerrond, L.; Newton, F.; Gelfand, R. Inhibiting cholesterol absorption with CP-88,818 (beta-tigogenin cellobioside; tiqueside): Studies in normal and hyperlipidemic subjects. J. Cardiovas. Pharmacol. 1997, 30, 55–60. [Google Scholar] [CrossRef]
- Xiao, J.X.; Peng, G.H.; Zhang, S.H. Prevention effects of soyasaponins on hyperlipidemia mice and its molecular mechanism. Acta Nutr. Sin. 2005, 27, 147–150. [Google Scholar]
- Lee, S.O.; Simons, A.L.; Murphy, P.A.; Hendrich, S. Soyasaponins lowered plasma cholesterol and increased fecal bile acids in female golden Syrian hamsters. Exp. Biol. Med. 2005, 230, 472–478. [Google Scholar] [CrossRef] [PubMed]
- Lee, I.A.; Park, Y.J.; Joh, E.H.; Kim, D.H. Soyasaponin Ab ameliorates colitis by inhibiting the binding of lipopolysaccharide (LPS) to Toll-like receptor (TLR)4 on macrophages. J. Agric. Food Chem. 2011, 59, 13165–13172. [Google Scholar] [CrossRef] [PubMed]
- Kang, J.; Sung, M.; Kawada, T.; Yoo, H.; Kim, Y.; Kim, J.; Yu, R. Soybean saponins suppress the release of proinflammatory mediators by LPS-stimulated peritoneal macrophages. Cancer Lett. 2005, 230, 219–227. [Google Scholar] [CrossRef] [PubMed]
- Zha, L.; Mao, L.; Lu, X.; Deng, H.; Ye, J.; Chu, X.; Sun, S.; Luo, H. Anti-inflammatory effect of soyasaponins through suppressing nitric oxide production in LPSstimulated RAW 264.7 cells by attenuation of NF-κB-mediated nitric oxide synthase expression. Bioorg. Med. Chem. Lett. 2011, 21, 2415–2418. [Google Scholar] [CrossRef] [PubMed]
- Zha, L.; Chen, J.; Sun, S.; Mao, L.; Chu, X.; Deng, H.; Cai, J.; Li, X.; Liu, Z.; Cao, W. Soyasaponins can blunt inflammation by inhibiting the reactive oxygen speciesmediated activation of PI3K/Akt/NF-kB pathway. PLoS ONE 2014, 9, e107655. [Google Scholar] [CrossRef]
- Lee, I.; Park, Y.; Yeo, H.; Han, M.J.; Kim, D. Soyasaponin I attenuates TNBS-induced colitis in mice by inhibiting NF-κB pathway. J. Agric. Food Chem. 2010, 58, 10929–10934. [Google Scholar] [CrossRef]
- Lan, X.; Deng, K.; Zhao, J.; Chen, Y.; Xin, X.; Liu, Y.; Khan, I.A.; Yang, S.; Wang, T.; Wu, Q. New triterpenoid saponins from green vegetable soya beans and their antiinflammatory activities. J. Agric. Food Chem. 2017, 65, 11065–11072. [Google Scholar] [CrossRef]
- Yoshiki, Y.; Okubo, K. Active oxygen scavenging activity of DDMP (2,3-dihydroxyl-4H-pyran-4 one) saponin in soybean seed. Biosci. Biotechnol. Biochem. 1995, 59, 1556–1557. [Google Scholar] [CrossRef] [Green Version]
- Zheng, Q.; Wu, J.; Xiao, R.; Wang, X.; Shi, B.; Wei, Y. Effects of soyasaponin on cultured smooth muscle cell lipid peroxidation induced by insulin. J. Norman Bethune Univ. Med. Sci. 1998, 24, 455–457. [Google Scholar]
- Li, X.X.; Qu, L.; Dong, Y.Z.; Han, L.F.; Liu, E.W.; Fang, S.M.; Zhang, Y.; Wang, T. A review of recent research progress on the astragalus genus. Molecules 2014, 19, 18850–18880. [Google Scholar] [CrossRef] [Green Version]
- Xue, M.; Bian, Y.; Liu, Y.; Zhou, J.; Xu, J.; Zhang, L.; Huang, X. Danggui Buxue decoction ameliorates lipid metabolic defects involved in the initiation of diabetic atherosclerosis; identification of active compounds. J. Tradit Chin. Med. 2020, 40, 414–421. [Google Scholar] [PubMed]
- Fu, X.; Sun, Z.; Long, Q.; Tan, W.; Ding, H.; Liu, X.; Wu, L.; Wang, Y.; Zhang, W. Glycosides from Buyang Huanwu Decoction inhibit atherosclerotic inflammation via JAK/STAT signaling pathway. Phytomedicine 2022, 105, 154385. [Google Scholar] [CrossRef] [PubMed]
- Wang, N.; Zhang, X.; Ma, Z.; Niu, J.; Ma, S.; Wenjie, W.; Chen, J. Combination of tanshinone IIA and astragaloside IV attenuate atherosclerotic plaque vulnerability in ApoE(−/−) mice by activating PI3K/AKT signaling and suppressing TRL4/NF-kappaB signaling. Biomed. Pharmacother. 2020, 123, 109729. [Google Scholar] [CrossRef] [PubMed]
- Shao, X.; Liu, Z.; Liu, S.; Lin, N.; Deng, Y. Astragaloside IV alleviates atherosclerosis through targeting circ_0000231/miR-135a-5p/CLIC4 axis in AS cell model in vitro. Mol. Cell Biochem. 2021, 476, 1783–1795. [Google Scholar] [CrossRef]
- Kong, X.L.; Lyu, Q.; Zhang, Y.Q.; Kang, D.F.; Li, C.; Zhang, L.; Gao, Z.C.; Liu, X.X.; Wu, J.B.; Li, Y.L. Effect of astragaloside IV and salvianolic acid B on antioxidant stress and vascular endothelial protection in the treatment of atherosclerosis based on metabonomics. Chin. J. Nat. Med. 2022, 20, 601–613. [Google Scholar] [CrossRef]
- Zhu, Z.; Li, J.; Zhang, X. Astragaloside IV protects against oxidized low-density lipoprotein (ox-LDL)-induced endothelial cell injury by reducing oxidative stress and inflammation. Med. Sci. Monit. 2019, 25, 2132–2140. [Google Scholar] [CrossRef]
- Nie, Q.; Zhu, L.; Zhang, L.; Leng, B.; Wang, H. Astragaloside IV protects against hyperglycemia-induced vascular endothelial dysfunction by inhibiting oxidative stress and Calpain-1 activation. Life Sci. 2019, 232, 116662. [Google Scholar] [CrossRef]
- Qin, H.W.; Zhang, Q.S.; Li, Y.J.; Li, W.T.; Wang, Y. Molecular mechanism of astragaloside against atherosclerosis by regulating miR-17-5p and PCSK9/VLDLR signal pathway. Zhongguo Zhong Yao Za Zhi (Chin. J. Chin. Mater. Med.) 2022, 47, 492–498. [Google Scholar]
- Tian, H.; Wang, T.; Zhang, Y.; Pan, T.; Yao, S.; Yu, H.; Ma, K.; Wang, S. Astragaloside IV protects against C/EBP homologous protein-mediated apoptosis in oxidized low-density lipoprotein-treated macrophages by promoting autophagy. Eur. J. Pharmacol. 2022, 923, 174912. [Google Scholar] [CrossRef]
- Zhang, Y.; Du, M.; Wang, J.; Liu, P. Astragaloside IV relieves atherosclerosis and hepatic steatosis via MAPK/NF-kappaB signaling pathway in LDLR(−/−) mice. Front. Pharmacol. 2022, 13, 828161. [Google Scholar] [CrossRef]
- Ho, F.M.; Liao, Y.H.; Yang, A.J.; Lee Chao, P.D.; Hou, Y.C.; Huang, C.T.; Lin, S.R.; Lee, K.R.; Huang, K.C.; Lin, W.W. Anti-atherosclerotic action of Ger-Gen-Chyn-Lian-Tang and AMPK-dependent lipid lowering effect in hepatocytes. J. Ethnopharmacol. 2012, 142, 175–187. [Google Scholar] [CrossRef] [PubMed]
- Lee, A.Y.; Park, W.; Kang, T.W.; Cha, M.H.; Chun, J.M. Network pharmacology-based prediction of active compounds and molecular targets in Yijin-Tang acting on hyperlipidaemia and atherosclerosis. J. Ethnopharmacol. 2018, 221, 151–159. [Google Scholar] [CrossRef] [PubMed]
- Musumeci, D.; Roviello, G.N.; Montesarchio, D. An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies. Pharmacol. Therap. 2014, 141, 347–357. [Google Scholar] [CrossRef] [PubMed]
- Wang, R.; Wu, W.; Li, W.; Huang, S.; Li, Z.; Liu, R.; Shan, Z.; Zhang, C.; Li, W.; Wang, S. Activation of NLRP3 inflammasome promotes foam cell formation in vascular smooth muscle cells and atherogenesis via HMGB1. J. Am. Heart Assoc. 2018, 7, e008596. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ding, J.W.; Luo, C.Y.; Wang, X.A.; Zhou, T.; Zheng, X.X.; Zhang, Z.Q.; Yu, B.; Zhang, J.; Tong, X.H. Glycyrrhizin, a high-mobility group box 1 inhibitor, improves lipid metabolism and suppresses vascular inflammation in apolipoprotein E knockout mice. J. Vasc. Res. 2018, 55, 365–377. [Google Scholar] [CrossRef] [PubMed]
- Singh, G.B.; Zhang, Y.; Boini, K.M.; Koka, S. High mobility group box 1 mediates TMAO-induced endothelial dysfunction. Int. J. Mol. Sci. 2019, 20, 3570. [Google Scholar] [CrossRef] [Green Version]
- Gao, M.; Heng, X.; Jin, J.; Chu, W. Gypenoside XLIX ameliorate high-fat diet-induced atherosclerosis via regulating intestinal microbiota, alleviating inflammatory response and restraining oxidative stress in ApoE(−/−) mice. Pharmaceuticals 2022, 15, 1056. [Google Scholar] [CrossRef]
- Li, K.; Ma, C.; Li, H.; Dev, S.; He, J.; Qu, X. Medicinal value and potential therapeutic mechanisms of Gynostemma pentaphyllum (Thunb.) Makino and its derivatives: An overview. Curr. Top. Med. Chem. 2020, 19, 2855–2867. [Google Scholar] [CrossRef]
- Su, C.; Li, N.; Ren, R.; Wang, Y.; Su, X.; Lu, F.; Zong, R.; Yang, L.; Ma, X. Progress in the medicinal value, bioactive compounds, and pharmacological activities of Gynostemma pentaphyllum. Molecules 2021, 26, 6249. [Google Scholar] [CrossRef]
- Gou, S.H.; Huang, H.F.; Chen, X.Y.; Liu, J.; He, M.; Ma, Y.Y.; Zhao, X.N.; Zhang, Y.; Ni, J.M. Lipid-lowering, hepatoprotective, and atheroprotective effects of the mixture Hong-Qu and gypenosides in hyperlipidemia with NAFLD rats. J. Chin. Med. Assoc. 2016, 79, 111–121. [Google Scholar] [CrossRef]
- Gou, S.H.; Liu, B.J.; Han, X.F.; Wang, L.; Zhong, C.; Liang, S.; Liu, H.; Qiang, Y.; Zhang, Y.; Ni, J.M. Anti-atherosclerotic effect of Fermentum Rubrum and Gynostemma pentaphyllum mixture in high-fat emulsion- and vitamin D3-induced atherosclerotic rats. J. Chin. Med. Assoc. 2018, 81, 398–408. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Q.; Guo, X.; Xie, C.; Cao, Z.; Wang, X.; Liu, L.; Yang, P. Unraveling the metabolic pathway of choline-TMA-TMAO: Effects of gypenosides and implications for the therapy of TMAO related diseases. Pharmacol. Res. 2021, 173, 105884. [Google Scholar] [CrossRef] [PubMed]
- Qi, G.; Zhang, L.; Li, C. Influence of gypenoside on serum lipoprotein and atherosclerosis in hyperlipidaemia animals. Zhongguo Zhong Yao Za Zhi (Chin. J. Chin. Mater. Med.) 1996, 21, 562–564. [Google Scholar]
- Aktan, F.; Henness, S.; Roufogalis, B.D.; Ammit, A.J. Gypenosides derived from Gynostemma pentaphyllum suppress NO synthesis in murine macrophages by inhibiting iNOS enzymatic activity and attenuating NF-kappaB-mediated iNOS protein expression. Nitric Oxide 2003, 8, 235–242. [Google Scholar] [CrossRef]
- Quan, Y.; Qian, M.Z. Effect and mechanism of gypenoside on the inflammatory molecular expression in high-fat induced atherosclerosis rats. Zhongguo Zhong Xi Yi Jie He Za Zhi 2010, 30, 403–406. [Google Scholar]
- Quan, Y.; Yang, Y.; Wang, H.; Shu, B.; Gong, Q.H.; Qian, M. Gypenosides attenuate cholesterol-induced DNA damage by inhibiting the production of reactive oxygen species in human umbilical vein endothelial cells. Mol. Med. Rep. 2015, 11, 2845–2851. [Google Scholar] [CrossRef] [Green Version]
- Xie, W.; Li, L.; Gong, D.; Zhang, M.; Lv, Y.C.; Guo, D.M.; Zhao, Z.W.; Zheng, X.L.; Zhang, D.W.; Dai, X.Y.; et al. Kruppel-like factor 14 inhibits atherosclerosis via mir-27a-mediated down-regulation of lipoprotein lipase expression in vivo. Atherosclerosis 2019, 289, 143–161. [Google Scholar] [CrossRef]
- Song, N.; Jia, L.; Cao, H.; Ma, Y.; Chen, N.; Chen, S.; Lv, X.; Yang, G. Gypenoside inhibits endothelial cell apoptosis in atherosclerosis by modulating mitochondria through PI3K/Akt/Bad pathway. BioMed Res. Int. 2020, 2020, 2819658. [Google Scholar] [CrossRef]
- Hui, B.; Hou, X.; Liu, R.; Liu, X.H.; Hu, Z. Gypenoside inhibits ox-LDL uptake and foam cell formation through enhancing Sirt1-FOXO1 mediated autophagy flux restoration. Life Sci. 2021, 264, 118721. [Google Scholar] [CrossRef]
- Huang, Y.P.; Wang, Y.S.; Liu, Y.Y.; Jiang, C.H.; Wang, J.; Jiang, X.Y.; Liu, B.W.; Wang, L.; Ye, W.C.; Zhang, J.; et al. Chemical characterization and atherosclerosis alleviation effects of Gypenosides from Gynostemma pentaphyllum through ameliorating endothelial dysfunction via the PCSK9/LOX-1 pathway. J. Agric. Food Chem. 2022, 70, 11944–11957. [Google Scholar] [CrossRef]
- Xie, P.; Guo, M.; Xie, J.B.; Xiao, M.Y.; Qi, Y.S.; Duan, Y.; Li, F.F.; Piao, X.L. Effects of heat-processed Gynostemma pentaphyllum on high-fat diet-fed mice of obesity and functional analysis on network pharmacology and molecular docking strategy. J. Ethnopharmacol. 2022, 294, 115335. [Google Scholar] [CrossRef] [PubMed]
- Huang, T.H.; Tran, V.H.; Roufogalis, B.D.; Li, Y. Gypenoside XLIX, a naturally occurring gynosaponin, PPAR-alpha dependently inhibits LPS-induced tissue factor expression and activity in human THP-1 monocytic cells. Toxicol. Appl. Pharmacol. 2007, 218, 30–36. [Google Scholar] [CrossRef] [PubMed]
- Huang, T.H.; Tran, V.H.; Roufogalis, B.D.; Li, Y. Gypenoside XLIX, a naturally occurring PPAR-alpha activator, inhibits cytokine-induced vascular cell adhesion molecule-1 expression and activity in human endothelial cells. Eur. J. Pharmacol. 2007, 565, 158–165. [Google Scholar] [CrossRef] [PubMed]
- Yang, K.; Zhang, H.; Luo, Y.; Zhang, J.; Wang, M.; Liao, P.; Cao, L.; Guo, P.; Sun, G.; Sun, X. Gypenoside XVII prevents atherosclerosis by attenuating endothelial apoptosis and oxidative stress: Insight into the ERalpha-mediated PI3K/Akt pathway. Int. J. Mol. Sci. 2017, 18, 77. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, D.; Wang, X. Diosgenin and its analogs: Potential protective agents against atherosclerosis. Drug Des. Devel. Ther. 2022, 16, 2305–2323. [Google Scholar] [CrossRef] [PubMed]
- Zhang, S.; Li, L.; Deng, M.; Wang, Y.; Shen, A.; Zhang, L. Di’ao Xinxuekang: Therapeutic potential in cardiovascular diseases. Curr. Mol. Pharmacol. 2021, 14, 975–985. [Google Scholar] [CrossRef]
- Ondeykal, J.G.; Herath, K.B.; Jayasuriya, H.; Polishook, J.D.; Bills, G.F.; Dombrowski, A.W.; Mojena, M.; Koch, G.; DiSalvo, J.; DeMartino, J.; et al. Discovery of structurally diverse natural product antagonists of chemokine receptor CXCR3. Mol. Divers. 2005, 9, 123–129. [Google Scholar] [CrossRef]
- Wu, S.; Xu, H.; Peng, J.; Wang, C.; Jin, Y.; Liu, K.; Sun, H.; Qin, J. Potent anti-inflammatory effect of dioscin mediated by suppression of TNF-alpha-induced VCAM-1, ICAM-1and EL expression via the NF-kappaB pathway. Biochimie 2015, 110, 62–72. [Google Scholar] [CrossRef]
- Wang, P.; He, L.Y.; Shen, G.D.; Li, R.L.; Yang, J.L. Inhibitory effects of Dioscin on atherosclerosis and foam cell formation in hyperlipidemia rats. Inflammopharmacology 2017, 25, 633–642. [Google Scholar] [CrossRef]
- Bao, R.; Wang, W.; Chen, B.; Pan, J.; Chen, Q.; Liu, M.; Wang, D.; Wu, Y.; Yu, H.; Han, L.; et al. Dioscin ameliorates hyperuricemia-induced atherosclerosis by modulating of cholesterol metabolism through FXR-signaling pathway. Nutrient 2022, 14, 1983. [Google Scholar] [CrossRef]
- Fan, T.; He, J.; Yin, Y.; Wen, K.; Kang, Y.; Zhao, H.; Chen, S.; Li, X. Dioscin inhibits intimal hyperplasia in rat carotid artery balloon injury model through inhibition of the MAPK-FoxM1 pathway. Eur. J. Pharmacol. 2019, 854, 213–223. [Google Scholar] [CrossRef]
- Duan, H.; Zhang, Q.; Liu, J.; Li, R.; Wang, D.; Peng, W.; Wu, C. Suppression of apoptosis in vascular endothelial cell, the promising way for natural medicines to treat atherosclerosis. Pharmacol. Res. 2021, 168, 105599. [Google Scholar] [CrossRef] [PubMed]
- Yang, Q.; Wang, C.; Jin, Y.; Ma, X.; Xie, T.; Wang, J.; Liu, K.; Sun, H. Disocin prevents postmenopausal atherosclerosis in ovariectomized LDLR−/− mice through a PGC-1alpha/ERalpha pathway leading to promotion of autophagy and inhibition of oxidative stress, inflammation and apoptosis. Pharmacol. Res. 2019, 148, 104414. [Google Scholar] [CrossRef] [PubMed]
- Yuan, B.; Yang, R.; Ma, Y.; Zhou, S.; Zhang, X.; Liu, Y. A systematic review of the active saikosaponins and extracts isolated from Radix Bupleuri and their applications. Pharm. Biol. 2017, 55, 620–635. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kim, B.M. The Role of saikosaponins in therapeutic strategies for age-related diseases. Oxidative Med. Cell. Longev. 2018, 2018, 8275256. [Google Scholar] [CrossRef]
- Zhou, P.; Shi, W.; He, X.Y.; Du, Q.Y.; Wang, F.; Guo, J. Saikosaponin D: Review on the antitumour effects, toxicity and pharmacokinetics. Pharm. Biol. 2021, 59, 1480–1489. [Google Scholar] [CrossRef]
- Huang, C.; Qiu, S.; Fan, X.; Jiao, G.; Zhou, X.; Sun, M.; Weng, N.; Gao, S.; Tao, X.; Zhang, F.; et al. Evaluation of the effect of Shengxian Decoction on doxorubicin-induced chronic heart failure model rats and a multicomponent comparative pharmacokinetic study after oral administration in normal and model rats. Biomed. Pharmacother. 2021, 144, 112354. [Google Scholar] [CrossRef]
- Yang, L.; Liu, J.; Qi, G. Mechanism of the effect of saikosaponin on atherosclerosis in vitro is based on the MAPK signaling pathway. Mol. Med. Rep. 2017, 16, 8868–8874. [Google Scholar] [CrossRef] [Green Version]
- He, D.; Wang, H.; Xu, L.; Wang, X.; Peng, K.; Wang, L.; Liu, P.; Qu, P. Saikosaponin-a attenuates oxidized LDL uptake and prompts cholesterol efflux in THP-1 cells. J. Cardiovasc. Pharmacol. 2016, 67, 510–518. [Google Scholar] [CrossRef]
- Chang, W.C.; Hsu, F.L. Inhibition of platelet activation and endothelial cell injury by flavan-3-ol and saikosaponin compounds. Prostaglandins Leukot Essent Fat. Acids 1991, 44, 51–56. [Google Scholar] [CrossRef]
- Liu, L.; Cheng, Y.; Zhang, H. Phytochemical analysis of anti-atherogenic constituents of Xue-Fu-Zhu-Yu-Tang using HPLC-DAD-ESI-MS. Chem. Pharm. Bull. 2004, 52, 1295–1301. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liu, S.; Tan, Z.; Li, P.; Gao, X.; Zeng, Y.; Wang, S. HepG2 cells biospecific extraction and HPLC-ESI-MS analysis for screening potential antiatherosclerotic active components in Bupeuri radix. J. Pharm. Biomed. Anal. 2016, 121, 56–62. [Google Scholar] [CrossRef] [PubMed]
- Wu, J.; Yang, G.; Zhu, W.; Wen, W.; Zhang, F.; Yuan, J.; An, L. Anti-atherosclerotic activity of platycodin D derived from roots of Platycodon grandiflorum in human endothelial cells. Biol. Pharm. Bull. 2012, 35, 1216–1221. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hu, C.; Zhang, Z.; Song, G.; Zhu, L.; Wang, R.; Ruan, Z. Jujuboside A ameliorates myocardial apoptosis and inflammation in rats with coronary heart disease by inhibiting PPAR-alpha signaling pathway. Evid.-Based Complementary Altern. Med. 2022, 2022, 2285728. [Google Scholar] [CrossRef]
- Asgary, S.; Moshtaghian, J.; Hosseini, M.; Siadat, H. Effects of alfalfa on lipoproteins and fatty streak formation in hypercholesterolemic rabbits. Pak. J. Pharm. Sci. 2008, 21, 460–464. [Google Scholar]
- Gu, Y.; Xiao, Z.H.; Wu, J.; Guo, M.; Lv, P.; Dou, N. Anti-atherosclerotic effect of afrocyclamin A against vascular smooth muscle cells is mediated via p38 MAPK signaling pathway. Cell J. 2021, 23, 191–198. [Google Scholar]
- Luo, Y.; Lu, S.; Gao, Y.; Yang, K.; Wu, D.; Xu, X.; Sun, G.; Sun, X. Araloside C attenuates atherosclerosis by modulating macrophage polarization via Sirt1-mediated autophagy. Aging 2020, 12, 1704–1724. [Google Scholar] [CrossRef]
- Feriani, A.; Tir, M.; Hachani, R.; Gomez-Caravaca, A.M.; Contreras, M.D.M.; Taamalli, A.; Talhaoui, N.; Segura-Carretero, A.; Ghazouani, L.; Mufti, A.; et al. Zygophyllum album saponins prevent atherogenic effect induced by deltamethrin via attenuating arterial accumulation of native and oxidized LDL in rats. Ecotoxicol. Environ. Saf. 2020, 193, 110318. [Google Scholar] [CrossRef]
- Fereydouni, Z.; Amirinezhad Fard, E.; Mansouri, K.; Mohammadi Motlagh, H.R.; Mostafaie, A. Saponins from Tribulus terrestris L. extract down-regulate expression of ICAM-1, VCAM-1 and E-selectin in human endothelial cell lines. Int. J. Mol. Cell Med. 2020, 9, 73–83. [Google Scholar]
- Wang, L.X.; Wu, Z.; Liu, Z.Y.; Jin, F.Y.; Zhao, Y.F.; Tu, P.F.; Zheng, J. Inhibitory effect of BF523 from Ilex hainanensis on ox LDL-induced foam cells formation. Zhongguo Zhong Yao Za Zhi (Chin. J. Chin. Mater. Med.) 2019, 44, 2680–2685. [Google Scholar]
- Liu, J.; Jiang, C.; Ma, X.; Wang, J. Notoginsenoside Fc attenuates high glucose-induced vascular endothelial cell injury via upregulation of PPAR-gamma in diabetic Sprague-Dawley rats. Vasc. Pharmacol. 2018, 109, 27–35. [Google Scholar] [CrossRef] [PubMed]
- Luo, Y.; Meng, X.; Zhou, P.; Lu, S.; Qin, M.; Xu, X.; Sun, G.; Sun, X. Elatoside C protects against ox-LDL-induced HUVECs injury by FoxO1-mediated autophagy induction. Biochim. Biophys. Acta Mol. Basis Dis. 2017, 1863, 1654–1665. [Google Scholar] [CrossRef] [PubMed]
- Yan, S.; Zhang, X.; Zheng, H.; Hu, D.; Zhang, Y.; Guan, Q.; Liu, L.; Ding, Q.; Li, Y. Clematichinenoside inhibits VCAM-1 and ICAM-1 expression in TNF-alpha-treated endothelial cells via NADPH oxidase-dependent IkappaB kinase/NF-kappaB pathway. Free Rad. Biol. Med. 2015, 78, 190–201. [Google Scholar] [CrossRef] [PubMed]
- Li, M.; Guan, Y.; Liu, J.; Zhai, F.; Zhang, X.; Guan, L. Cellular and molecular mechanisms in vascular smooth muscle cells by which total saponin extracted from Tribulus terrestris protects against artherosclerosis. Cell Physiol. Biochem. 2013, 32, 1299–1308. [Google Scholar] [CrossRef] [PubMed]
- Afrose, S.; Hossain, M.S.; Maki, T.; Tsujii, H. Karaya root saponin exerts a hypocholesterolemic response in rats fed a high-cholesterol diet. Nutr. Res. 2009, 29, 350–354. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Luo, H.; Chen, J.; Su, C.; Zha, L. Advances in the Bioactivities of Phytochemical Saponins in the Prevention and Treatment of Atherosclerosis. Nutrients 2022, 14, 4998. https://doi.org/10.3390/nu14234998
Luo H, Chen J, Su C, Zha L. Advances in the Bioactivities of Phytochemical Saponins in the Prevention and Treatment of Atherosclerosis. Nutrients. 2022; 14(23):4998. https://doi.org/10.3390/nu14234998
Chicago/Turabian StyleLuo, Huiyu, Junbin Chen, Chuhong Su, and Longying Zha. 2022. "Advances in the Bioactivities of Phytochemical Saponins in the Prevention and Treatment of Atherosclerosis" Nutrients 14, no. 23: 4998. https://doi.org/10.3390/nu14234998